{"id":20359,"date":"2021-01-21T14:23:00","date_gmt":"2021-01-21T14:23:00","guid":{"rendered":"https:\/\/celonpharma.com\/?p=20359"},"modified":"2021-01-21T14:23:00","modified_gmt":"2021-01-21T14:23:00","slug":"current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us","status":"publish","type":"post","link":"https:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/","title":{"rendered":"Current report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US"},"content":{"rendered":"<p>Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US<\/p>\n<p>Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 confidential information, time: 4:42 PM<\/p>\n<p>Content of the report:<\/p>\n<p>Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) wishes to announce that on January 18, 2021, it received information that the Company was granted a patent covering GPR40 receptor agonists and their use in type diabetes treatment in the US.<\/p>\n<p>The patent was granted by the United States Patent and Trademark Office and guarantees full legal protection of the compounds covered by the patent and their use in treating the above-mentioned conditions in the United States of America.<\/p>\n<p>Celon Pharma S.A. develops GPR40 (CPL\u2019280) in treatment of type 2 diabetes and diabetic neuropathies and that compound successfully completed phase I clinical trials.<\/p>\n<p>The obtained patent protection reduces the risk associated with the project and increases the value of the Company&#8217;s potential products in the therapeutic areas covered by patent protection.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 confidential information, time: 4:42 PM Content of the report: Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) wishes to announce that on January 18, 2021,<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/\" title=\"ReadCurrent report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-20359","post","type-post","status-publish","format-standard","hentry","category-current-report"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Current report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US - CelonGROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US - CelonGROUP\" \/>\n<meta property=\"og:description\" content=\"Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 confidential information, time: 4:42 PM Content of the report: Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) wishes to announce that on January 18, 2021,Read more &raquo;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/\" \/>\n<meta property=\"og:site_name\" content=\"CelonGROUP\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-21T14:23:00+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/\",\"url\":\"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/\",\"name\":\"Current report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US - CelonGROUP\",\"isPartOf\":{\"@id\":\"https:\/\/celon.group\/en\/#website\"},\"datePublished\":\"2021-01-21T14:23:00+00:00\",\"author\":{\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\"},\"breadcrumb\":{\"@id\":\"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/celon.group\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/celon.group\/en\/#website\",\"url\":\"https:\/\/celon.group\/en\/\",\"name\":\"CelonGROUP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/celon.group\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\",\"name\":\"Ma\u0142gorzata Siewierska\",\"url\":\"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US - CelonGROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/","og_locale":"en_US","og_type":"article","og_title":"Current report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US - CelonGROUP","og_description":"Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 confidential information, time: 4:42 PM Content of the report: Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) wishes to announce that on January 18, 2021,Read more &raquo;","og_url":"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/","og_site_name":"CelonGROUP","article_published_time":"2021-01-21T14:23:00+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/","url":"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/","name":"Current report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US - CelonGROUP","isPartOf":{"@id":"https:\/\/celon.group\/en\/#website"},"datePublished":"2021-01-21T14:23:00+00:00","author":{"@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf"},"breadcrumb":{"@id":"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/celon.group\/en\/2021\/01\/21\/current-report-no-3-2021-obtaining-a-patent-for-gpr40-receptor-agonists-and-their-use-in-t2d-treatment-in-the-us\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celon.group\/en\/"},{"@type":"ListItem","position":2,"name":"Current report No. 3\/2021 \u2013 Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US"}]},{"@type":"WebSite","@id":"https:\/\/celon.group\/en\/#website","url":"https:\/\/celon.group\/en\/","name":"CelonGROUP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celon.group\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf","name":"Ma\u0142gorzata Siewierska","url":"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/"}]}},"_links":{"self":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/20359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/comments?post=20359"}],"version-history":[{"count":0,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/20359\/revisions"}],"wp:attachment":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media?parent=20359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/categories?post=20359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/tags?post=20359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}